Literature DB >> 19731633

HLA-B27 and host-pathogen interaction.

Anna S Sahlberg1, Kaisa Granfors, Markus A Penttinen.   

Abstract

HLA-B27 is a risk factor closely associated to spondyloarthropathies (SpA). One form of SpA is reactive arthritis (ReA), which develops as a complication after certain bacterial infections (e.g., Salmonellae, Yersiniae, Shigellae, Campylobacteriae and Chlamydiae). The development of infection-triggered complication is a complex train of events between the triggering bacteria and the host. Since most of the patients suffering from ReA are HLA-B27 positive, it has been proposed that HLA-B27 may modulate the interaction between ReA-triggering bacteria and host cell. Besides antigen presenting function, HLA-B27 displays other unusual properties that might be of importance in the development of ReA. These properties (homodimer formation and misfolding of HLA-B27 heavy chain in the endoplasmic reticulum (ER)) may trigger ER-stress signaling pathways in host cell, which in turn may modulate cell signaling in favor of ReA-triggering bacteria. Here we summarize the observations of HLA-B27 modulating the interaction between ReA-triggering bacteria and host cell and discuss potential mechanisms behind the interaction.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19731633     DOI: 10.1007/978-1-4419-0298-6_17

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  2 in total

1.  Pathogen safety of long-term treatments for bleeding disorders: still relevant to current practice.

Authors:  Giovanni Di Minno; Mariana Canaro; James W Ironside; David Navarro; Carlo Federico Perno; Andreas Tiede; Lutz Gürtler
Journal:  Haematologica       Date:  2013-10       Impact factor: 9.941

2.  HLA-B27 modulates intracellular growth of Salmonella pathogenicity island 2 mutants and production of cytokines in infected monocytic U937 cells.

Authors:  Shichao Ge; Qiushui He; Kaisa Granfors
Journal:  PLoS One       Date:  2012-03-28       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.